tumour markers

tumour markers

Substances in the blood or urine that indicate, often by abnormal levels, the presence of a malignant tumour in the body. They include proteins such as thyroglobulin and immunoglobulins; glycoproteins such as the prostate-specific antigen (PSI) and CA-125; hormonal peptides such as beta-human chorionic gonadotrophin and adrenocorticotrophic hormone; enzymes such as lactate dehydrogenase and prostatic acid phosphatase; tumour-associated carbohydrate antigens; neuromediators such as catecholamines; oncogenes; oncofetal antigens such as alpha-fetoprotein and carcinoembryonic antigen; and cytogenic markers such as the Philadelphia chromosome.
References in periodicals archive ?
These blood samples were centrifuged for 10 minutes at 3500 rpm, and then serums were separated and kept frozen at -80 [degrees]C until the tumour markers were studied.
M2 PHARMA-November 10, 2014-Study finds examination of combined tumour markers could help diagnose pancreatic cancer
Unfortunately, only few tumour markers have been identified for early stage cancers to date, and the reliable detection of tumours before the manifestation of morphological changes still remains an unresolved problem in routine clinical diagnosis.
Tumour markers are a valuable addition to the test panel used for monitoring disease progression.
Tumour markers are substances that are produced either by the tumour itself or by the body in response to the presence of cancer or certain benign (noncancerous) conditions that can aid in the diagnosis of cancer and in the assessment of tumour burden.
By contrast, the European Group on Tumour Markers (EGTM) recommends the use of markers during follow-up [18].
As high sensitivity and specificity and different cut-off values have been reported for mucin-like carcinoma associated antigen (MCA), this molecule was with the other tumour markers and MCA-CA15.
20] will begin to have a greater impact in clinical practice and continued educational efforts by organizations such as the American Association for Clinical Chemistry, the National Academy of Clinical Biochemistry, and European Group on Tumour Markers will impart the effectiveness and limitations of such testing upon the minds of the caregivers.
The search for tumour markers which would be effective in screening high-risk subjects is an active area of cancer research [7].
Lead by Institute Director, Anthony Fields, MD, results of this study were reported in June 1995 at the 12th Annual International Conference on Human Tumour Markers in New York City.
The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer.

Full browser ?